Home › Trials › NCT06830629

Evaluating MZE829 for Kidney Disease Related to APOL1 Genotype

An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype

Phase 2 Interventional Maze Therapeutics · NCT06830629

This study is testing a new treatment called MZE829 to see if it can help adults with kidney disease related to a specific genetic marker and reduce protein in their urine.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment56 (estimated)
Ages18 Years to 68 Years
SexAll
SponsorMaze Therapeutics Industry-sponsored
Locations81 sites (Decatur, Alabama and 80 other locations)
Trial IDNCT06830629 on ClinicalTrials.gov

What this trial studies

This Phase 2 study aims to assess the safety, tolerability, and impact of MZE829 on albuminuria in adults suffering from proteinuric chronic kidney disease associated with the APOL1 high-risk genotype. The study is open-label, meaning all participants will know they are receiving the treatment. It specifically targets individuals with chronic kidney disease who have persistent albuminuria and possess certain genetic markers. The trial will monitor participants for any adverse effects while measuring changes in kidney function.

Who should consider this trial

Good fit: Ideal candidates include adults with the APOL1 high-risk genotype and chronic kidney disease characterized by persistent albuminuria.

Not a fit: Patients with organ transplants, recent cancer history, or certain other medical conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly reduce albuminuria and improve kidney function in patients with APOL1-mediated kidney disease.

How similar studies have performed: While this approach is novel, similar studies targeting genetic factors in kidney disease have shown promise in the past.

Eligibility criteria

Show full inclusion / exclusion criteria 
Key Inclusion Criteria:

* APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2
* Chronic kidney disease with persistent albuminuria

Key Exclusion Criteria:

* Organ or bone marrow transplantation
* History of cancer within past 2 years, excepted for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer
* Conditions that may alter drug absorption, e.g., history of bariatric surgery
* Type I diabetes
* Pregnant or currently nursing

Other inclusion/exclusion criteria defined in protocol apply.

Where this trial is running

Decatur, Alabama and 80 other locations

+31 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Proteinuric Kidney DiseaseAPOL1-mediated kidney diseaseAPOL1 kidney disease
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.